JCEM:诊断前和长期随访期间库欣综合征患者精神药物使用情况

2021-02-15 MedSci原创 MedSci原创

诊断前已观察到CD患者精神药物使用量增加,无论缓解状态如何,表明其对患者精神健康的不良影响持续存在

精神症状在库欣综合征(CD)患者中很常见,并且在治疗后似乎只能部分逆转。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在调查治疗前和长期随访期间CD患者与精神症状发病相关的药物处方情况。

该研究以全国纵向登记中心为基础进行的研究,研究人员从瑞典垂体病登记中心确定了1990年至2018年间诊断出的CD患者(N=372)。纵向数据是从5年前、诊断时和随访期间进行收集。每位患者纳入了四名匹配的对照者。研究人员还对76例持续缓解的患者进行了横断面亚组分析。该研究的主要结局指标数据来自瑞典处方药登记机构和患者登记机构。

在5年前和诊断时,CD患者使用抗抑郁药(OR为2.2 [95%CI为1.3-3.7]和2.3[1.6-3.5])、抗焦虑药(2.9 [1.6-5.3]和3.9 [2.3-6.6])和安眠药(2.1 [1.2-3.7]和3.8 [2.4-5.9])相比于对照者更频繁。抗抑郁药(2.4 [1.5-3.9])和安眠药(3.1 [1.9-5.3])在5年随访中OR仍然升高。在诊断时和5年随访后,使用抗抑郁药(26%)和安眠药(22%)的CD患者比例没有变化,而用于高血压和糖尿病的药物减少了。持续缓解中位数为9.3年(IQR为8.1-10.4)的患者使用抗抑郁药(OR为2.0 [1.1-3.8])和安眠药(2.4 [1.3-4.7])的几率较高,但不用于高血压治疗的药物并未变化。

由此可见,诊断前已观察到CD患者精神药物使用量增加,无论缓解状态如何,表明其对患者精神健康的不良影响持续存在。这项研究强调了早期诊断CD的重要性,以及对精神健康进行长期监测的必要性。

原始出处:

Daniel Bengtsson.et al.Psychotropic drugs in patients with Cushing’s disease before diagnosis and at long-term follow-up - a nationwide study.JCEM.2021.https://doi.org/10.1210/clinem/dgab079

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
    2021-06-01 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
    2021-03-23 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2063407, encodeId=30e6206340e23, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Jun 01 22:02:53 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778025, encodeId=3ac81e78025f7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 23 21:02:53 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967223, encodeId=0446196e223cb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon Mar 01 21:02:53 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660847, encodeId=6b83166084e49, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Sep 08 19:02:53 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971594, encodeId=d7bc19e1594d8, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 25 20:02:53 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432008, encodeId=ce6f1432008e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586759, encodeId=4c871586e5968, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Wed Feb 17 06:02:53 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924806, encodeId=57e092480628, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210131/b35591bafe2a4b869917b577adba9fab/c267322e38334bd6a95a8340ea85f70c.jpg, createdBy=f36b1426385, createdName=6322400001, createdTime=Mon Feb 15 21:57:37 CST 2021, time=2021-02-15, status=1, ipAttribution=)]
    2021-02-15 6322400001

    好文

    0

相关资讯

JCEM:库欣综合征患者的海马体积、认知功能、抑郁、焦虑和生活质量分析

由此可见,目前的研究并未提示CS患者的海马体积减少。然而,大多数患者认知领域受到显著影响,并且对手术反应良好。CS患者出现抑郁症状和HRQoL降低,术后有所改善。

Lancet Diabetes Endo:左旋酮康唑治疗库欣综合征

研究认为,每日两次口服左旋酮康唑治疗可持续改善尿游离皮质醇,可作为库欣综合征的一种有效的治疗方法

Lancet Diabetes Endocrinol:库欣综合征药物治疗前沿进展

20世纪50年代,因为缺乏有效治疗手段,库欣综合征患者的平均存活仅4.6年。半个多世纪后的今天,随着医学知识和技术的不断更新和飞速发展,库欣综合征患者的寿命得到大幅延长,但死亡率仍是正常人群的1.7~4.8倍。及时诊断和治疗库欣综合征非常重要。2018年7月,发表在《Lancet Diabetes Endocrinol》的一篇综述对库欣综合征药物治疗最新进展情况进行了阐述。

42岁女高管疯了,人也变丑了,医生撩起她裤腿那瞬间找到幕后真凶,还她清白!

今天的病人是一个42岁的女高管。前面已经讲过一个女高管的故事,这是另外一个惊心动魄、跌宕起伏的女高管的故事。

病例:胰腺腺泡细胞癌伴异位ACTH综合征一例

患者男性,27岁。以“体检发现胰腺占位性病变2月”入院。

Osilodrostat:歪打正着的治疗库欣综合征的创新药物

3月7日,FDA批准诺华的Isturisa(osilodrostat)上市,用于治疗库欣综合征。这是FDA批准的首个口服11‐β‐羟化酶抑制剂。商品名:Isturisa,患者无论是否接受受过